This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 

UK appeals court upholds Genentech patent


England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor (hVEGF) antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea.

Genentech, hVEGF, Regeneron, Bayer, Trap Eye, patent, Court of Appeal


Payment types accepted